Biosimilars Guidances To Focus On Naming, Tracking, Defining “Protein”
This article was originally published in The Pink Sheet Daily
Executive Summary
Without offering a timeline for release, CDER’s Rachel Sherman says the documents will also address exclusivity issues, as well as specifying what constitutes “publicly available” information regarding FDA’s previous determination of safety, purity and potency.